1 Guidance

1 Guidance

1.1 Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non‑Hodgkin's lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.

  • National Institute for Health and Care Excellence (NICE)